Non-endometrioid adenocarcinoma of the uterine corpus: A review of selected histological subtypes

Cancer Control

Volumn 16, Issue 1, 2009, Pages 46-52

  Mendivil, Alberto ^a   Schuler, Kevin M ^b   Gehrig, Paola A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ABDOMINAL RADIOTHERAPY; ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CLEAR CELL CARCINOMA; CYTOLOGY; CYTOREDUCTIVE SURGERY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; HISTOLOGY; HYSTERECTOMY; LYMPHADENECTOMY; METASTASIS; MUCINOUS CARCINOMA; MULTIPLE CYCLE TREATMENT; PAPILLARY CARCINOMA; PARAAORTIC LYMPHADENECTOMY; PELVIS LYMPHADENECTOMY; PERITONEAL CAVITY; PROGNOSIS; REVIEW; SALPINGOOOPHORECTOMY; SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; CLINICAL TRIAL; FEMALE; GYNECOLOGIC SURGERY; HUMAN; PATHOLOGY; RADIOTHERAPY; UTERUS CANCER;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; PROGNOSIS; RADIOTHERAPY; UTERINE NEOPLASMS;

EID: 61449477498     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480901600107     Document Type: Review

References (51)

1. Jemal A. Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96. Epub 2008 Feb 20.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-17.
3. Dunton CJ, Balsara G, McFarland M, et al. Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv. 1991;46(2):97-102.
4. Creasman WT, Odicino F, Maisonneuve R et al. Carcinoma of the corpus uteri: FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S1Q5-S143.
5. Hendrickson y, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6(2):93-108.
6. Cavanagh D, Fiorica JV, Hoffman MS, et al. Adenocarcinoma of the endometrium: an institutional review. Cancer Control. 1999;6(4):354-360.
7. Sherman ME, Bitterrnan P, Rosenshein NB, et al. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopatho-logic features. Am J Surg Pathol. 1992;16(6):600-610.
8. Fadare O, Zheng W. Endometrial glandular dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers. Diagn Pathol. 2008;3:6.
9. RisingerJI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998;4(12):3005-3010.
10. Maxwell GL, RisingerJI, Alvarez AA, et al. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol. 2001 ;97(3):417-422.
11. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29(6):551-558.
12. Herzog TJ, Kowalski LD, Liu H, et al. Evaluation of a region on chromosome 1 p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma. Gynecol Oncol. 2001;82(1):139-142.
13. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol. 2007;46(1):26-32.
14. An HJ, Logani S, Isacson C, et al. Molecular characterization of uterine clear cell carcinoma. Mod Pathol. 2004;17(5):530-537.
15. Abramovich D, Markman M, Kennedy A, et al. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. J Cancer Res Clin Oncol. 1999;125(12):697-698.
16. Price FV, Chambers SK, Carcangiu ML, et al. CA 125 may not reflect disease status in patients with uterine serous carcinoma. Cancer. 1998;82(9): 1720-1725.
17. Havrilesky LJ, Secord AA, Bae-Jump V, et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007;105(3): 677-682. Epub 2007 Mar 13.
18. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642-646.
19. Creasman WT, Morrow CR Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 1987;60(8 suppl):2035-2041.
20. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994;54(3):264-268.
21. Geisler JP, Geisler HE, Melton ME, et al. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol. 1999;74(3):465-467.
22. Bristow RE, Asrari F, Trimble EL, et al. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol. 2001;81(2):279-286.
23. Chan JK, Loizzi V, Youssef M, et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol. 2003;90(1):181-185.
24. Sutton G, Axelrod JH, Bundy BN, et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100(2):349-354. Epub 2005 Oct 5.
25. Fakiris AJ, Moore DH, Reddy SR, et al. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uter- ine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study. Gynecol Oncol. 2005;96(3):818-823.
26. Huh WK, Powell M, Leath CA 3rd, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol. 2003;91 (3):470-475.
27. Dietrich CS 3rd, Modesitt SC, DePriest PD, et al. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2005;99(3):557-563. Epub 2005 Sep 8.
28. Kelly MG, O'Malley DM, Hui R et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol. 2005;98(3):353-359.
29. Fader AN, Drake R, O'Malley D, et al. Effect of adjuvant platinum/ taxane chemotherapy with or without radiation therapy in uterine papillary serous carcinoma. Gynecol Oncol. 2008;108:S60. Abstract.
30. Zanotti KM, Belinson JL, Kennedy AW, et al. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol. 1999;74(2):272-277.
31. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91(3):483-469.
32. Ramondetta L, Burke TW, Levenback C, et al. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol. 2001 ;82(1 ): 156-161.
33. Grice J, Ek M, Greer B, et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol. 1998;69(1):69-73.
34. Gehrig PA, Morris DE, Van Le L. Uterine serous carcinoma: a comparison of therapy for advanced-stage disease. Int J Gynecol Cancer. 2004; 14(3):515-520.
35. Sutton G, Axelrod JH, Bundy BN, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2005;97(3): 755-763.
36. Low JS, Wong EH, Tan HS, et al. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol Oncol. 2005;97(1):171-177.
37. Alvarez Secord A, Havrilesky LJ, Bae-Jump V, et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol. 2007;107(2):285-291. Epub 2007 Aug 6.
38. Homesley HD, Filiaci V, Gibbons SK, et al. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:S1. Abstract.
39. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(1):36-44. Epub 2005 Dec 5.
40. Abeler VM, Kjørstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol. 1991 ;40(3): 207-217.
41. Matthews RR Hutchinson-Colas J, Maiman M, et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol. 1997;65(2):206-212.
42. Murphy KT, Rotmensch J, Yamada SD, et al. Outcome and patterns of failure in pathologic stages l-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003;55(5):1272-1276.
43. Thomas M, Mariani A, Wright JD, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol. 2008;108(2):293-297. Epub 2007 Dec 21.
44. Cirisano FD Jr, Robboy SJ, Dodge RK, et al. The outcome of stage Ml clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol. 2000;77(1):55-65.
45. Abeler VM, Vergote IB, Kjørstad KE, et al. Clear cell carcinoma of the endometrium: prognosis and metastatic pattern. Cancer. 1996;78(8):1740-1747.
46. DiSaia PJ, Creasman WT. Clinical Gynecologic Oncology. 6th ed. St. Louis, MO: Mosby Inc; 2002.
47. Acharya S, Hensley ML, Montag AC, et al. Rare uterine cancers. Lancet Oncol. 2005;6(12):961-971.
48. Giordano G, D'AddaT, Gnetti L, et al. Endometrial mucinous microg-landular adenocarcinoma: morphologic, immunohistochemical features, and emphasis in the human papillomavirus status. Int J Gynecol Pathol. 2006;25(1):77-82.
49. Thomakos N, Galaal K, Godfrey KA, et al. Primary endometrial squamous cell carcinoma. Arch Gynecol Obstet. 2008;278(2):177-180. Epub 2008 Jan 31.
50. Goodman A, Zukerberg LR, Rice LW, et al. Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature. Gynecol Oncol. 1996;61(1):54-60.
51. Kennedy AS, DeMars LR, Flannagan LM, et al. Primary squamous cell carcinoma of the endometrium: a first report of adjuvant chemoradia-tion. Gynecol Oncol. 1995;59(1):117-123.